- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05068011
차등 표적 다중화 척수 자극 (DETECT)
차등 표적 다중화 척수 자극: 다기관 코호트 연구
Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle/surgical leads versus percutaneous leads.
연구 개요
연구 유형
등록 (추정된)
연락처 및 위치
연구 장소
-
-
-
Antwerp, 벨기에
- ZNA
-
Bruges, 벨기에
- AZ Sint-Jan Brugge-Oostende
-
Bruges, 벨기에
- AZ Sint-Lucas Brugge
-
Hasselt, 벨기에
- Jessa Ziekenhuis
-
Kortrijk, 벨기에
- AZ Groeninge
-
Leuven, 벨기에
- UZ Leuven
-
Lier, 벨기에
- Heilig Hart Ziekenhuis Lier
-
Liège, 벨기에
- Centre Hospitalier Régional (CHR) de la Citadelle
-
Mechelen, 벨기에
- AZ Sint-Maarten
-
Roeselare, 벨기에
- AZ Delta
-
Sint-Niklaas, 벨기에
- Vitaz
-
Turnhout, 벨기에
- AZ Turnhout
-
Wilrijk, 벨기에
- GZA
-
-
Brussels Capital
-
Jette, Brussels Capital, 벨기에, 1090
- Universitair Ziekenhuis Brussel
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients with chronic back and leg pain due to Failed Back Surgery Syndrome (FBSS)/Persistent Spinal Pain Syndrome type 2 (PSPS-T2), who will receive treatment with differential target multiplexed (DTM) SCS.
설명
Inclusion Criteria:
- Patients with severe chronic pain (> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician
- Age > 18 years
- Patient has been informed of the study procedures and has given written informed consent
- Patient willing to comply with study protocol including attending the study visits
Exclusion Criteria:
- Expected inability of the patient to receive or properly operate the spinal cord stimulation system
- History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew
- Active malignancy
- Addiction to drugs, alcohol (>5 units per day) and/or medication
- Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and/or ability to evaluate treatment outcome as determined by investigator
- Immune deficiency (e.g. HIV positive, immunosuppressive treatment)
- Life expectancy < 1 year
- Local infection or any other skin disorder at site of incision
- Pregnancy
- Other implanted active medical device
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Spinal cord stimulation
Patients will receive differential target multiplexed spinal cord stimulation |
differential target multiplexed stimulation |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall pain intensity with Visual Analogue Scale (VAS)
기간: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Overall pain, defined as a combination of back and leg pain, but not pain from other body parts, measured with the VAS (100mm) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
VAS(Visual Analogue Scale)를 사용한 요통 강도
기간: DTM 자극 후 1개월, 6개월 및 12개월 후 기준선 스크리닝과 평가 사이의 변화
|
DTM 자극 후 1개월, 6개월 및 12개월 후 기준선 스크리닝과 평가 사이의 변화
|
|
|
VAS(Visual Analogue Scale)를 통한 다리 통증 강도
기간: DTM 자극 후 1개월, 6개월 및 12개월 후 기준선 스크리닝과 평가 사이의 변화
|
DTM 자극 후 1개월, 6개월 및 12개월 후 기준선 스크리닝과 평가 사이의 변화
|
|
|
임상 전체론적 응답자 상태
기간: DTM 자극 후 1개월, 6개월 및 12개월 후 기준선 스크리닝과 평가 사이의 변화
|
DTM 자극 후 1개월, 6개월 및 12개월 후 기준선 스크리닝과 평가 사이의 변화
|
|
|
성공적인 DTM 시험의 비율.
기간: 최종 SCS 이식 후 평가
|
최종 SCS 이식 후 평가
|
|
|
배터리 소모
기간: DTM SCS의 1개월, 6개월 및 12개월에 등록
|
DTM SCS의 1개월, 6개월 및 12개월에 등록
|
|
|
DTM SCS 프로그래밍과 관련된 기술적 문제의 확산
기간: 공부기간 내내
|
공부기간 내내
|
|
|
DTM SCS 자극 파라미터
기간: DTM SCS의 1개월, 6개월 및 12개월에 등록
|
DTM SCS의 1개월, 6개월 및 12개월에 등록
|
|
|
Pain medication use
기간: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Open question regarding the dosage, frequency and type of pain medication |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Functional disability
기간: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The functional disabilities will be assessed with the Oswestry Disability Index (ODI) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Health related quality of life
기간: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Health related quality of life, evaluated with the EuroQol with five dimensions and 5 levels |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Patient global impression of change
기간: Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
Patients will be asked to quantify the impression of change after treatment using the Patient Global Impression of Change scale (PGIC). |
Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
|
Patients' individual competencies for self-management
기간: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Patient activation measure-13 (PAM) is a 13-item instrument which assesses self-reported behaviour, knowledge, and confidence for self-management of one's health. |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Work status
기간: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Work status is evaluated with a self-designed questionnaire |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Pain catastrophizing
기간: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Pain Catastrophizing Scale (PCS) will be used to measure the level of pain catastrophizing |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Symptoms of central sensitisation.
기간: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Central Sensitization Inventory is used to measure symptoms of central sensitisation |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Anxiety and Depression.
기간: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The hospital Anxiety and Depression Scale (HADS) will measure symptoms of anxiety and depression |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Healthcare utilisation.
기간: The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
Postoperative healthcare expenditure will be investigated by self-reporting methods. |
The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
|
Time spent in body postures
기간: The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
Based on the AdaptiveStim technology, the time spent in body postures can be recorded. |
The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
|
(Serious) adverse events
기간: Throughout study period
|
Systematically recording all adverse events |
Throughout study period
|
|
Patient expectations concerning SCS
기간: Evaluated at baseline visit
|
Self-constructed open question to evaluate patient expectations about SCS |
Evaluated at baseline visit
|
공동 작업자 및 조사자
스폰서
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- DETECT
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .